Nektar Therapeutics (NKTR) PT Raised to $89.00 at Mizuho

Nektar Therapeutics (NASDAQ:NKTR) had its price target hoisted by investment analysts at Mizuho from $45.00 to $89.00 in a report issued on Monday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Mizuho’s price target points to a potential upside of 24.32% from the company’s previous close.

Several other equities research analysts have also recently issued reports on the stock. Canaccord Genuity restated a “buy” rating and set a $80.00 price objective (up from $50.00) on shares of Nektar Therapeutics in a research report on Wednesday, January 10th. Zacks Investment Research cut shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Jefferies Group restated a “buy” rating and set a $35.00 price objective on shares of Nektar Therapeutics in a research report on Wednesday, November 8th. JPMorgan Chase & Co. restated a “buy” rating and set a $44.00 price objective on shares of Nektar Therapeutics in a research report on Monday, November 13th. Finally, Cowen began coverage on shares of Nektar Therapeutics in a research report on Tuesday, November 7th. They set an “outperform” rating for the company. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have given a buy rating to the company’s stock. Nektar Therapeutics currently has an average rating of “Buy” and an average target price of $46.17.

Shares of Nektar Therapeutics (NKTR) opened at $71.59 on Monday. The company has a market cap of $11,273.11, a PE ratio of -99.43 and a beta of 1.81. The company has a debt-to-equity ratio of 2.91, a current ratio of 4.14 and a quick ratio of 3.99. Nektar Therapeutics has a 12-month low of $11.41 and a 12-month high of $75.33.

Nektar Therapeutics (NASDAQ:NKTR) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.37 EPS for the quarter, beating the Zacks’ consensus estimate of $0.21 by $0.16. The business had revenue of $152.90 million during the quarter, compared to analysts’ expectations of $126.50 million. Nektar Therapeutics had a negative net margin of 42.08% and a negative return on equity of 190.68%. The company’s quarterly revenue was up 321.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.32) earnings per share. sell-side analysts anticipate that Nektar Therapeutics will post -0.76 EPS for the current fiscal year.

In other Nektar Therapeutics news, CEO Howard W. Robin sold 83,333 shares of the stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $55.69, for a total transaction of $4,640,814.77. Following the completion of the transaction, the chief executive officer now owns 272,768 shares of the company’s stock, valued at $15,190,449.92. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Howard W. Robin sold 83,334 shares of the stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $23.57, for a total transaction of $1,964,182.38. Following the transaction, the chief executive officer now directly owns 235,838 shares of the company’s stock, valued at approximately $5,558,701.66. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 614,017 shares of company stock valued at $20,587,527. 5.44% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of NKTR. Oppenheimer Asset Management Inc. purchased a new position in shares of Nektar Therapeutics in the third quarter valued at approximately $129,000. Mark Sheptoff Financial Planning LLC boosted its stake in shares of Nektar Therapeutics by 79.4% in the third quarter. Mark Sheptoff Financial Planning LLC now owns 6,100 shares of the biopharmaceutical company’s stock valued at $146,000 after purchasing an additional 2,700 shares during the period. Flinton Capital Management LLC boosted its stake in shares of Nektar Therapeutics by 75.7% in the second quarter. Flinton Capital Management LLC now owns 7,872 shares of the biopharmaceutical company’s stock valued at $154,000 after purchasing an additional 3,392 shares during the period. Riverhead Capital Management LLC boosted its stake in shares of Nektar Therapeutics by 78.7% in the second quarter. Riverhead Capital Management LLC now owns 8,754 shares of the biopharmaceutical company’s stock valued at $171,000 after purchasing an additional 3,854 shares during the period. Finally, Sicart Associates LLC purchased a new position in shares of Nektar Therapeutics in the fourth quarter valued at approximately $245,000. 96.00% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Nektar Therapeutics (NKTR) PT Raised to $89.00 at Mizuho” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/01/22/nektar-therapeutics-nktr-pt-raised-to-89-00-at-mizuho.html.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Leave a Reply